Clairvoyant Therapeutics
VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints.
"We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out in February 2024 and a top line read out in Q2 2024," stated Damian Kettlewell, CEO, Clairvoyant.
"Our goal is to be the first company in the world to obtain regulatory approval for the clinical use of psilocybin in AUD. The medical benefits of psychedelic compounds like psilocybin have been supressed for decades. We are pleased that regulatory authorities are now engaged in evidence-based approaches to review these potentially remarkable compounds."
Clairvoyant has been motivated to explore psilocybin therapy for AUD as a result of pioneering academic work by researchers in the U.S. Positive clinical results will support Clairvoyant's goal to help millions of AUD patients around the world.
Alcohol is the leading risk factor for overall burden of disease among men and a significant risk factor among women (source: WHO Global Status Report on Alcohol and Health 2014). A regional study recently reported that fewer than 5 per cent of patients diagnosed with moderate to severe alcohol use disorder receive recommended medications (source: BC Centre for Substance Use, 2023).
About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Canadian biotechnology company trailblazing a path to global mental health through psilocybin therapy. Clairvoyant's speed-to-market clinical strategy is designed to enable psilocybin therapy in the EU, UK & Canada to treat patients living with Alcohol Use Disorder (AUD) beginning in 2026.
The company's exceptional team, with deep clinical development experience, has made Clairvoyant the most advanced company developing psilocybin therapy for the treatment of AUD. Clairvoyant is a member of Life Sciences BC.
Additional information about Clairvoyant's clinical trial may be found at ClinicalTrials.gov
-30-
For more information:
Damian Kettlewell
damian@clairvoyantrx.com
SOURCE: Clairvoyant Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/810748/clairvoyant-surpasses-50-per-cent-randomization-in-its-phase-2b-psilocybin-therapy-trial-for-alcohol-use-disorder
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Movella Holdings Inc. Announces Completion of Corporate Restructuring6.5.2025 10:30:00 CEST | Press release
LOS ANGELES, CA / ACCESS Newswire / May 6, 2025 / Movella Holdings Inc. (the "Company") today announced the completion of a restructuring transaction involving its wholly-owned subsidiary, Movella Inc. ("Movella"), and its existing secured lenders. In connection with the transaction, Movella, the Company, certain of its subsidiaries, FP Credit Partners II AIV, L.P. and FP Credit Partners Phoenix II AIV, L.P. (the "FP Noteholders"), and FP Credit Partners II, L.P. and FP Credit Partners Phoenix II, L.P. (the "FP Shareholders") entered into a Restructuring Agreement (the "Restructuring Agreement") in response to continuing events of default under the Note Purchase Agreement, dated as of November 14, 2022 (the "Note Purchase Agreement"), pursuant to which Movella had previously issued secured promissory notes to the FP Noteholders with the Company as a guarantor of the secured promissory notes. Pursuant to the Restructuring Agreement and related transactions (the "Restructuring Transactio
Loar Holdings Inc. Announces Date and Time for First Quarter 2025 Earnings Conference Call6.5.2025 08:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 6, 2025 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2025 earnings before the market opens on Tuesday, May 13, 2025. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations
Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D6.5.2025 08:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / May 6, 2025 / A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers impeding the global fight against hepatitis delta. Also known as hepatitis D, hepatitis delta is a severe liver disease affecting an estimated 12 million people worldwide. It occurs in people living with hepatitis B, leads to faster disease progression, and significantly increases the risk of liver cancer and death. The Hepatitis Delta Global Landscape Survey collected responses from 583 individuals across 102 countries, providing the most comprehensive picture to date of global stakeholder perspectives on awareness, testing, and treatment access around hepatitis delta. Key Findings: There are pronounced regional variations in reported availability and accessibility of hepatitis delta testing and treatment. Even where hepatitis delta testing and treatment are reported to be available, acces
Camino Announces Exploration Results at Los Chapitos and Further Exploration Plans in Peru6.5.2025 06:00:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / May 6, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) (WKN: A116E1) ("Camino" or the "Company") is pleased to announce exploration results at its Copper-Silver stratabound Los Chapitos copper project ("Los Chapitos" or the "Project"), including drilling and additional mapping, trenching, and sampling along both the La Estancia and Diva copper mineralized trends. The Company is targeting large-scale disseminated manto-type copper-silver mineralization to support resource delineation studies at Los Chapitos. Camino and its partner Nittetsu Mining Co., Ltd. ("Nittetsu") plan to commence the next phase of drilling in the second half of 2025. The Los Chapitos copper project is located near the coastal city of Chala in the department of Arequipa in Peru. Juan Carlos Castelli, Consulting Geologist from Chile, said "the Los Chapitos property is inside the northern continuation of the metallogenic Cu-Ag belt defined in Northern Chile, with operat
OMP Achieves Top Two Rankings in Four Use Cases in the 2025 Gartner Critical Capabilities for Supply Chain Planning Solutions Report6.5.2025 05:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / May 6, 2025 / OMP, a global leader in supply chain planning solutions, has achieved four second-highest scores across five Use Cases, evaluated in the 2025 Gartner® Critical Capabilities for Supply Chain Planning Solutions report. This report, a companion to the Gartner Magic Quadrant™, assesses the vendors of the SCP solutions evaluated in this research. This recognition follows OMP's recent position as highest on the Ability to Execute axis in the 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions - marking the tenth consecutive time OMP is named a Leader. Consistent strength across real-world planning challenges The Critical Capabilities report evaluates 20 vendors on 15 key capabilities across five SCP Use Cases. We believe OMP's scores, particularly in supply planning, decision/plan alignment, and the breadth of resource types, demonstrate its strong performance in these critical areas. "Supply chains today need real solutions that de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom